MRK - Merck in-licenses Evaxion vaccine candidate in a deal worth up to $600M
2025-09-25 08:04:48 ET
More on Evaxion Biotech ADS, Merck
- Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
- Merck: Buy This Dividend Powerhouse While It's Cheap
- Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Trump administration formally links Tylenol use in pregnancy to autism
- Trump considering website for consumers to buy discounted prescription drugs - report